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ABSTRACT
Introduction: Postoperative pain management
can be challenging in patients with a high body
mass index (BMI) especially as a result of poor
venous access and delayed ambulation that can
result in serious complications. Fentanyl
iontophoretic transdermal system (ITS) is a
needle-free, patient-controlled analgesic
method available for use in acute
postoperative pain. The primary objective of
these analyses was to determine if there were
any differences between patients with high BMI
([40 kg/m2) and lower BMIs (\30 kg/m2 and
35–40 kg/m2) in terms of efficacy or safety.
Methods: Data from three registration,
placebo-controlled trials and three
active-comparator trials using fentanyl ITS
(IONSYS, The Medicines Company,
Parsippany, NJ) for the management of
postoperative pain were analyzed using BMI
categories of \35 kg/m2, 35–40 kg/m2, and
[40 kg/m2. The majority of patients had lower
abdominal or orthopedic surgery. For these
analyses, the primary efficacy variables were
assessed via patient global assessment of pain
control (PGA) at 24 h and investigator global
assessment (IGA) at study discharge. PGA and
IGA are categorical 4-point scales (excellent,
good, fair, or poor) with treatment ‘‘success’’
defined as either excellent or good. Safety was
evaluated via treatment emergent adverse
events (TEAEs).
Results: There were 1403 patients randomly
assigned and treated with fentanyl ITS for at
least 3 h (BMI \35 kg/m2: 1180; 35–40 kg/m2:
136, BMI [40 kg/m2: 85; and 2 missing). PGA
treatment success, which evaluates the method
of pain control, at 24 h was consistent in the
high and low BMI groups in patients treated
with fentanyl ITS (\35 kg/m2: 946/1180
[80.2%]; 35–40 kg/m2: 103/136 [75.7%]; and
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[40 kg/m2: 65/85 [76.5%]). The IGA results at
study discharge were similar to the PGA. Safety
appeared similar with fentanyl ITS across the
BMI groups.
Conclusion: In these analyses, fentanyl ITS was
as efficacious, as assessed by the PGA ratings of
treatment ‘‘success’’, in patients with high BMI
([40 kg/m2) as it was for those with lower BMIs
(\35 kg/m2 or 35–40 kg/m2) and was generally
well tolerated across all BMI categories.
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Almost one-third of adults in the USA are obese
(body mass index [BMI] of 30 kg/m2 or greater)
[1]. Worldwide obesity has doubled since 1980
[2], and more patients who are obese are
undergoing bariatric surgery as a method for
weight control. Patients with a BMI greater than
40 kg/m2 or a BMI between 35 kg/m2 and 40 kg/
m2 with co-morbid conditions are potential
candidates for bariatric surgery. In addition,
obesity is associated with other co-morbid
chronic medical conditions such as
orthopedic, cardiac, and pulmonary disease
that make these patients more challenging to
manage postoperatively. In these obese patients
especially, successful postoperative pain
management is critical with dual goals of
reducing or eliminating pain and regaining
mobility as quickly as possible [3]. Opioids
continue to be the mainstay of most
postoperative multimodal therapy. However,
appropriate concern about adverse events such
as respiratory depression or oversedation in
patients with obesity and challenges with
venous access may lead to undertreatment of
pain.
Fentanyl iontophoretic transdermal system
(ITS) (IONSYS, The Medicines Company,
Parsippany, New Jersey) is a pre-programmed,
needle-free drug delivery system used to deliver
patient-controlled analgesia (PCA) for acute
postoperative pain in adult patients during
hospitalization. Fentanyl is administered via
iontophoresis which is a transdermal delivery
of fentanyl through the skin via the application
of a low-intensity electrical field [4]. Fentanyl
ITS delivers doses based on patient demand.
Unlike traditional PCA, no venous access or
intravenous (IV) lines are needed to apply or
administer the fentanyl ITS system. Given the
increasing number of obese patients as well as
the increasing number of surgical procedures
being performed in this population, it is
important to evaluate the relative efficacy and
safety of fentanyl ITS in the obese population.
The existing phase 3 dataset provides an initial
opportunity to explore these questions. The
primary purpose of these analyses was to
determine if there were any differences
between patients with high BMI and lower
BMIs in terms of efficacy or safety. A
secondary outcome was to compare fentanyl
ITS versus morphine IV PCA to evaluate if the
efficacy profile was similar between the two
treatments by BMI category.
METHODS
Trials were included in these analyses if they
studied the fentanyl iontophoretic transdermal
system in prospective randomized controlled
trials and also included BMI. A literature search
resulted in five unique clinical trials that are
included in these analyses [5–9]. One additional
study was not included as BMI data was not
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available [10]. The manufacturer provided
details for this analysis on a 6th phase 3 trial
that has not been published. This represents all
of the phase 3/3B trials conducted utilizing
fentanyl ITS. The details of each trial are
presented in Table 1.
In all studies, patients admitted to the
postanesthesia care unit after major surgery
were titrated to comfort with opioids prior to
receiving study drug. All studies utilized the
validated patient global assessment of the
method of pain control (PGA) [11]. The PGA is
a categorical 4-point scale (excellent, good, fair,
or poor) with treatment success defined as
excellent or good. The PGA was the primary
outcome of the four active-comparator phase 3B
trials. The PGA is rated by the patient directly
and does not reflect the treating clinician or
investigator’s assessment. While the PGA was
not designed as a patient-reported outcome
instrument, it is a patient-reported instrument
to assess the method of pain control. In the
validation paper the authors concluded that
‘‘The PGA of the method of pain control is an
informative and useful measure for assessing
pain control provided by different drug delivery
systems for patients experiencing postoperative
pain.’’ The studies also utilized the investigator
global assessment of the method of pain control
(IGA). The IGA is a similar categorical 4-point
scale to the PGA with treatment success defined
as excellent or good. Safety was assessed via
treatment-emergent adverse events (TEAEs). For
purposes of these analyses, the following
subgroups were utilized: \35 kg/m2, 35–40 kg/
m2, and [40 kg/m2. These group definitions
were selected on the basis of indication
prerequisites for bariatric surgery which
currently includes a BMI of at least 40 kg/m2
or a BMI of 35 kg/m2 or more with a serious
health problem linked to obesity [12]. Five of
the six studies have been previously published
with full methodology [5–9]. The sixth study
was a placebo-controlled trial similar in design
to the other two placebo-controlled trials. The
primary purpose of these analyses was to
determine if there were any differences
between patients with high BMI and lower
BMIs in terms of efficacy or safety. A
secondary purpose was to evaluate if there
were any differences between patients treated
with fentanyl ITS versus morphine IV PCA
across the BMI categories.
Compliance with Ethics Guidelines
All studies received applicable institutional
review board approval prior to initiation. All
patients who had participated in the studies
provided written informed consent prior to
study enrollment. All procedures performed
were in accordance with the ethical standards
of the institutional and/or national research
committee and with the 1964 Declaration of
Helsinki, as revised in 2013.
Statistical Analysis
The evaluable efficacy population included
patients who had at least 3 h of study
treatment, consistent with the analyses for the
original phase 3 trials. The safety population
included all patients who received any study
treatment, also referred to as the treated
population.
Descriptive statistics were utilized for most
variables, including the analysis of PGA, IGA,
and safety. A meta-analysis was conducted on
the secondary outcomes comparing fentanyl
ITS with morphine IV PCA for the PGA and IGA
and was performed according to the Cochrane
methodology [13]. The meta-analysis was
conducted using random effects models [13],






































































































































































































































































































































































































































































































































































































































































































































































































































secondary analyses. For dichotomous variables,
odds ratios (ORs) indicating the probability of
the outcome occurring were calculated.
Statistical tests were performed at the 0.05
significance level, with no multiplicity
adjustments. Ninety-five percent confidence
intervals (CIs) were provided for all parameters.
Only patients with observations at the given
time points were included in the calculations.
Any missing values were excluded from
analyses.
RESULTS
In the controlled studies included in these
analyses there were a total of 1436 patients
randomized to fentanyl ITS. There were 1212
who had BMIs\35 kg/m2, 138 who had a BMI
C35 kg/m2 and B40 kg/m2, and 86 who had a
BMI[40 kg/m2. In the placebo-controlled trials
there were 316 patients randomized to placebo.
Of these, there were 271 who had BMIs\35 kg/
m2, 30 who had a BMI[35 kg/m2 and B40 kg/
m2, and 15 who had a BMI [40 kg/m2. In the
active-comparator trials there were 977 patients
randomized to morphine IV PCA. Of these,
there were 802 who had BMIs \35 kg/m2, 112
who had a BMI[35 kg/m2 and B40 kg/m2, and
63 who had a BMI[40 kg/m2. The demographic
and baseline characteristics across the BMI
categories for fentanyl ITS, morphine IV PCA,
and placebo are presented in Table 2. The
majority of patients were female and white.
The groups were similar across all treatments
and BMI categories; however, there were fewer
patients in the [40 kg/m2 group who
underwent orthopedic surgery compared to
the other two BMI categories.
The mean number of fentanyl ITS doses used
in the first 24 h across the BMI categories was 32



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in patients with BMI C35 kg/m2 and B40 kg/m2,
and 32 doses in patients with BMI [40 kg/m2.
The mean number of doses of morphine IV PCA
used in the first 24 h across the BMI categories
was 39 doses in patients with BMI \35 kg/m2,
46 doses in patients with BMI C35 kg/m2 and
B40 kg/m2, and 40 doses in patients with BMI
[40 kg/m2. The mean number of doses of
placebo ITS used in the first 24 h across the
BMI categories was 24 doses in patients with
BMI\35 kg/m2, 19 doses in patients with BMI
C35 kg/m2 and B40 kg/m2, and 30 doses in
patients with BMI[40 kg/m2.
The magnitude of treatment ‘‘success’’ on the
PGA at 24 h was similar in the high BMI groups and
the lowBMIgroup inpatients treatedwith fentanyl
ITS (\35 kg/m2: 946/1180 [80.2%]; 35–40 kg/m2:
103/136 [75.7%]; and[40 kg/m2: 65/85 [76.5%])
(Table 3). Similarly, the magnitude of patients
rating their method of treatment as ‘‘excellent’’ at
24 h onthePGAwasconsistentacross thehighand
low BMI groups (Table 3). The IGA results at study
discharge were similar between BMI categories for
either treatment ‘‘success’’ or rating of ‘‘excellent’’
(Table 3).
Analyzing the active-comparator trials, the
proportion of patients with treatment ‘‘success’’
or rated as ‘‘excellent’’ on the PGA was
comparable between fentanyl ITS and
morphine IV PCA for the high and low BMI
categories (Fig. 1a, b). Similarly, treatment
‘‘success’’ or ratings of ‘‘excellent’’ according to
the IGA was comparable between fentanyl ITS
and morphine IV PCA across high and low BMI
categories (Fig. 1c, d).
The most common TEAEs were nausea,
pyrexia, vomiting, headache, and application
site erythema across all of the BMI categories in
the patients randomized and treated with
fentanyl ITS (Table 4). There were a similar
number of patients in the morphine IV PCA
group who experienced these same AEs;
however, pyrexia was seen in more morphine
IV PCA patients than in fentanyl ITS patients
and application site erythema was unique to
fentanyl ITS.












Patient global assessment at 24 h
Success 946 (80.2) 103 (75.7) 65 (76.5)
Excellent 564 (47.8) 57 (41.9) 42 (49.4)
Investigator global assessment at last assessment
Success 988 (83.7) 106 (77.9) 62 (72.9)
Excellent 691 (58.6) 66 (48.5) 50 (58.8)
The patient global assessment of the method of pain control and the investigator global assessment of the method of pain
control are categorical 4-point scales (excellent, good, fair, or poor) with treatment ‘‘success’’ deﬁned as ratings of either
excellent or good
BMI body mass index, ITS iontophoretic transdermal system, IV PCA intravenous patient-controlled analgesia
Pain Ther
< 35 649/787 (82.5%)  639/788 (81.1%)  1.104 (0.853, 1.430 ) 0.4508 
35 to 40 76/99 (76.8%) 98/112 (87.5%) 0.486 (0.233, 1.013) 0.0542 
>40 47/63 (74.6%) 51/63 (81.0%) 0.683 (0.292, 1.600) 0.3806 
All Patients  772/949 (81.3%)  788/963 (81.8%)  0.967 (0.767, 1.221) 0.7801 
< 35 375/787 (47.6%) 277/788 (35.2%)  1.688 (1.363, 2.092) <0.0001 
35 to 40 42/99 (42.4%) 53/112 (47.3%) 0.821 (0.444, 1.518) 0.53 
>40 30/63 (47.6%) 23/63 (36.5%) 1.570 (0.764, 3.226) 0.2192 
All Patients 447/949 (47.1%) 353/963 (36.7%)  1.530 (1.219, 1.919) 0.0002 
< 35 684/787 (86.9%)  663/788 (84.1%)  1.259 (0.948, 1.673) 0.1117 
35 to 40 79/99 (79.8%)  102/112 (91.1%)  0.419 (0.155, 1.130) 0.0857 
>40 48/63 (76.2%)  56/63 (88.9%)  0.663 (0.301, 1.458) 0.3067 
All Patients  811/949 (85.5%) 822/963 (85.4%)  1.007 (0.780, 1.229) 0.9602 
< 35 471/787 (59.8%) 306/788 (38.8%)  2.375 (1.868, 3.020) <0.0001 
35 to 40 50/99 (50.5%) 47/112 (42.0%) 1.350 (0.729, 2.500) 0.3403 
>40 36/63 (57.1%) 29/63 (46.0%) 1.455 (0.655, 3.235) 0.3572 





Fig. 1 Patient global assessment of a success and b rating
of excellent at 24 h. Investigator global assessment of
c success and d rating of excellent at last assessment. BMI
body mass index, CI conﬁdence interval, ITS
iontophoretic transdermal system, IV PCA intravenous
patient-controlled analgesia, OR odds ratio. There are no
statistically signiﬁcant differences in either the PGA or
the IGA between fentanyl ITS and morphine IV PCA
when compared by BMI group. The patient global
assessment of the method of pain control and the
investigator global assessment of the method of pain
control are categorical 4-point scales (excellent, good, fair,
or poor) with treatment ‘‘success’’ deﬁned as ratings of





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the controlled studies included in these
analyses there were 1436 patients who were
treated with fentanyl ITS. These phase 3 studies
were designed to be inclusive of a broad range of
weights, with no maximum BMI specified in the
inclusion/exclusion criteria. The distribution of
patients across BMIs was expectedly not even,
reflective of the surgical population; however,
there were a sizeable number of patients in the
higher BMI categories (138 with a BMI C35 kg/
m2 and B40 kg/m2, and 86 with a BMI[40 kg/
m2). Overall, treatment success, as assessed with
the PGA of the method of pain control, with
fentanyl ITS was 76.5% in the highest BMI
group ([40 kg/m2) group, which was consistent
with the results in the lower BMI categories.
Similar results were seen with the IGA.
Therefore, it appears that fentanyl ITS is
equally effective in the high and low BMI
categories. The comparison of fentanyl ITS to
morphine IV PCA by each BMI category showed
overall consistency between the two treatments
as assessed using either the PGA or IGA, further
supporting efficacy in high BMI patients.
Fentanyl and morphine are powerful
opioids; therefore, it is expected that the pain
control is similar between these two modalities
(fentanyl ITS and morphine IV PCA). However,
the additional benefits of fentanyl ITS relating
to the validated instruments of physical therapy
ease-of-care [14], nurse ease-of-care [15], and
patient ease-of-care [16] have been evaluated
and published in other analyses of the full phase
3 dataset. In addition, postoperative mobility is
important for every patient undergoing surgery
and especially so for obese patients. Early
patient mobilization has been shown to reduce
the cost of care and improve patient outcomes,
whereas immobility is associated with increased
complications, length of stays, and costs
[17–19]. Fentanyl ITS is an effective analgesic
in the postoperative period and also does not
require an IV line and associated equipment
(pumps, IV poles). Fentanyl ITS has
demonstrated in a double-blind clinical trial
that patients find it easier to mobilize when
compared to morphine IV PCA [20]. A previous
analysis evaluated mobility with fentanyl ITS
and morphine IV PCA and found that patients
treated with fentanyl ITS were better able to
mobilize in the postoperative period than those
treated with morphine IV PCA across high and
low BMI ranges that were assessed:\25 kg/m2;
25 kg/m2 to\30 kg/m2; 30 kg/m2 to\40 kg/m2;
and[40 kg/m2 [21].
Intravenous access can be challenging to
obtain and maintain in obese patients [22].
Notably, patients with poor venous access may
experience interruption of standard IV PCA. One
of the features of fentanyl ITS is that it reduces the
need for a separate IV line for PCA administration
in patients and therefore can be advantageous to
utilize in the obese patient population.
The mean number of doses of fentanyl ITS
utilized in the first 24 h did not differ between
the BMI categories. One research group has
previously shown that the G allele of the
OPRM1 gene encoding the mu receptor is
more common in patients who are obese [23].
This polymorphism has been associated with an
increase in the requirement for morphine and
fentanyl for pain relief. However, this was not
evident in these analyses. Neither fentanyl ITS
nor morphine IV PCA showed differences in
doses used between the BMI categories.
However, it is informative to note that as with
other PCA systems, the fentanyl ITS system
allows the patient to individualize their pain
management regimen; therefore, patients
requiring more fentanyl may take up to 80
doses in a 24-h period and those requiring less
can take less.
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Overall, the safety profile was generally
similar across the high and low BMI
categories. The TEAEs observed most often in
the fentanyl ITS group and morphine IV PCA
group are common to all opioids and include
nausea, pyrexia, vomiting, and headache.
Nausea, vomiting, and dizziness were all
slightly less common in the BMI [40 kg/m2
group compared to the BMI \35 kg/m2 group,
while headache was slightly more common in
the [40 kg/m2 group compared to the BMI
\35 kg/m2 and the 35–40 kg/m2 groups.
Respiratory depression is of particular
importance in an obese population and needs
to be carefully evaluated and monitored when
using opioids. In this analysis, in the fentanyl
ITS groups, hypoxia was reported in 3.3% of
patients with a BMI \35 kg/m2, in 2.2% of
patients with a BMI C35 kg/m2 to B40 kg/m2,
and in 1.2% of patients with a BMI[40 kg/m2.
In a meta-analysis that was performed using the
active-comparator trials, opioid-related adverse
events (including respiratory depression and
sedation) were assessed in the aggregate study
population [24]. During the development
program with more than 2500 patients treated
with fentanyl ITS, there were no patients treated
with fentanyl ITS who experienced clinically
relevant respiratory depression (CRRD), and
there were five patients in the morphine IV
PCA group who did experience CRRD [25].
However, despite the low rates of CRRD in the
clinical studies, it is still important to closely
monitor patients being treated with any opioid,
including fentanyl ITS, for signs of sedation and
respiratory depression. This is especially true for
patients who are obese and may be more
predisposed to these adverse events.
One limitation of these analyses is that none
of the studies were designed to specifically look at
BMI and therefore the population is not evenly
distributed between the categories. However,
this is a reasonably large sample of patients who
are obese or morbidly obese. Another limitation
is the selection of the BMI categories. These
categories were chosen for their clinical
relevance to reflect the categories that are
commonly used to assess for bariatric surgery
eligibility [12]; however, it is reassuring that
there was a great deal of consistency across the
BMI categories in terms of safety and efficacy. The
main purpose of these analyses was to evaluate
the safety and efficacy of fentanyl ITS in the high
and low BMI categories; however, we also
compared the efficacy and safety to morphine
IV PCA as there were fairly large sample sizes
available from the clinical trial database. Another
limitation of these studies, and therefore these
analyses, is that they do not factor in multimodal
analgesia treatment. It is important to remember
that the primary purpose of the studies included
was to evaluate the safety and efficacy of fentanyl
ITS for regulatory submissions and ultimately
drug approval and therefore multimodal
analgesia was not included in the methodology.
There were some additional endpoints that
would have been useful to have measured, such
as time to first bowel movement, time to getting
up from bed etc.; however, these were not
included in the design of the trials and
therefore there is no information contained to
specifically address these issues within the
database. Further research in patients with high
BMI using fentanyl ITS in multimodal treatment
would be useful to confirm and extend the
findings of this paper.
CONCLUSION
In these analyses, fentanyl ITS was as
efficacious, as assessed by the PGA for pain
control treatment ‘‘success’’, in patients with
high BMI ([40 kg/m2) as it was for those with
Pain Ther
lower BMIs (\35 kg/m2 or 35–40 kg/m2) and was
generally well tolerated across all BMI
categories. Therefore, the results suggest that
fentanyl ITS is a valuable option for the
short-term treatment of postoperative pain in
patients of all BMIs including the obese and
morbidly obese.
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